TY - JOUR T1 - Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 JF - medRxiv DO - 10.1101/2021.04.05.21254656 SP - 2021.04.05.21254656 AU - Parakkal Deepak AU - Wooseob Kim AU - Michael A. Paley AU - Monica Yang AU - Alexander B. Carvidi AU - Alia A. El-Qunni AU - Alem Haile AU - Katherine Huang AU - Baylee Kinnett AU - Mariel J. Liebeskind AU - Zhuoming Liu AU - Lily E. McMorrow AU - Diana Paez AU - Dana C. Perantie AU - Rebecca E. Schriefer AU - Shannon E. Sides AU - Mahima Thapa AU - Maté Gergely AU - Suha Abushamma AU - Michael Klebert AU - Lynne Mitchell AU - Darren Nix AU - Jonathan Graf AU - Kimberly E. Taylor AU - Salim Chahin AU - Matthew A. Ciorba AU - Patricia Katz AU - Mehrdad Matloubian AU - Jane A. O’Halloran AU - Rachel M. Presti AU - Gregory F. Wu AU - Sean P.J. Whelan AU - William J. Buchser AU - Lianne S. Gensler AU - Mary C. Nakamura AU - Ali H. Ellebedy AU - Alfred H.J. Kim Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/07/2021.04.05.21254656.abstract N2 - Background Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2 vaccination platforms provide robust protection in immunocompetent individuals, the immunogenicity in CID patients on immunosuppression is not well established. Therefore, determining the effectiveness of SARS-CoV-2 vaccines in the setting of immunosuppression is essential to risk-stratify CID patients with impaired protection and provide clinical guidance regarding medication management.Methods We conducted a prospective assessment of mRNA-based vaccine immunogenicity in 133 adults with CIDs and 53 immunocompetent controls. Blood from participants over 18 years of age was collected before initial immunization and 1-2 weeks after the second immunization. Serum anti-SARS-CoV-2 spike (S) IgG+ binding, neutralizing antibody titers, and circulating S-specific plasmablasts were quantified to assess the magnitude and quality of the humoral response following vaccination.Results Compared to immunocompetent controls, a three-fold reduction in anti-S IgG titers (P=0.009) and SARS-CoV-2 neutralization (p<0.0001) were observed in CID patients. B cell depletion and glucocorticoids exerted the strongest effect with a 36- and 10-fold reduction in humoral responses, respectively (p<0.0001). Janus kinase inhibitors and antimetabolites, including methotrexate, also blunted antibody titers in multivariate regression analysis (P<0.0001, P=0.0023, respectively). Other targeted therapies, such as TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors, had only modest impacts on antibody formation and neutralization.Conclusions CID patients treated with immunosuppressive therapies exhibit impaired SARS-CoV-2 vaccine-induced immunity, with glucocorticoids and B cell depletion therapy more severely impeding optimal responses.Competing Interest StatementP.D. participated in consulting, advisory board, or speaker's bureau for Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, AbbVie, and Arena Pharmaceuticals and received funding under a sponsored research agreement unrelated to the data in the paper from Takeda Pharmaceutical, Arena Pharmaceuticals, Bristol Myers Squibb-Celgene, and Boehringer Ingelheim. M.A.C. participated in consulting, advisory board, or speaker's bureau for AbbVie, Pfizer, Bristol Myers Squibb, and Theravance, and received funding under a sponsored research agreement unrelated to the data in the paper from Incyte, Pfizer, Janssen, and the Crohn's and Colitis Foundation. G.F.W. received honoraria for consulting for Novartis and Genentech and funding under a sponsored research agreement unrelated to the data in the paper from Biogen, EMD Serono, and Roche. The S.P.J.L. laboratory received funding under a sponsored research agreement unrelated to the data in the paper from Vir Biotechnology, AbbVie, and SAb therapeutics. L.S.G. received honoraria for consulting for AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB received funding under a sponsored research agreement unrelated to the data in the paper from Pfizer and UCB. The A.H.E. laboratory received funding under a sponsored research agreement unrelated to the data in the paper from Emergent BioSolutions and Abbvie. A.H.J.K. participated in consulting, advisory board, or speaker's bureau for Alexion Pharmaceuticals, Aurinia Pharmaceuticals, Annexon Biosciences, Exagen Diagnostics, Inc., and GlaxoSmithKilne and received funding under a sponsored research agreement unrelated to the data in the paper from GlaxoSmithKline. All other authors declare no competing interests.Funding StatementThis research was supported by The Leona M. and Harry B. Helmsley Charitable Trust, Washington University Digestive Disease Research Core Center (NIDDK P30DK052574), Washington University Rheumatic Diseases Research Resource-Based Center (NIAMS P30AR073752), The Judy Miniace Research Fund for the Washington University Lupus Clinic, and UCSF investigators were funded by PREMIER, a NIAMS P30 Center (P30AR070155) and the Russell/Engleman Rheumatology Research Center. This study utilized samples obtained from the Washington University School of Medicine's COVID-19 biorepository, which is supported by the Barnes-Jewish Hospital Foundation, the Siteman Cancer Center grant P30CA091842 from the National Cancer Institute of the National Institutes of Health, and the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the view of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Washington University School of Medicine Institutional Review Board (protocol #201105110, approved 01 June 2011; protocol #202012081, approved 21 December 2020; and protocol #202012084, approved 23 December 2020) and the UCSF Institutional Review Board (protocol #17-21898, approved 22 April 2017 and protocol #20-33078, approved 04 January 2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant data are available from the corresponding author upon reasonable request. ER -